Communiqués de presse Archive - Page 18 of 24 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes

OSE Immunotherapeutics Announces €10.7 Million in Additional Public Funding, via Bpifrance

OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement for FR 104

OSE Immunotherapeutics Announces First Peer-Reviewed Publication in Science Advances on OSE-230

OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of CoVepiT

OSE Immunotherapeutics Reports 2020 Financial Results

OSE Immunotherapeutics and ARCAGY – GINECO Announce Initiation of a Randomized Phase 2 Clinical Trial

OSE Immunotherapeutics to Present New Data at AACR 2021

OSE Immunotherapeutics Presentation at H.C. Wainwright Global Life Sciences Conference

OSE Immunotherapeutics Announces Granting of First European Patent Protecting OSE-127

OSE Immunotherapeutics Enters a Loan Agreement of up to €25 Million with the European Investment Bank

Précédent
1
…
15
16
17
18
19
20
21
…
24
Suivant